Skip to main content
XPH logo
XPH
(NYSEARCA)
State Street SPDR S&P Pharmaceuticals ETF
$70.38-- (--)
Loading... - Market loading

XPH ETF: State Street SPDR S&P Pharmaceuticals ETF - Price, Holdings & Analysis

State Street SPDR S&P Pharmaceuticals ETF Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fund characteristics, expense ratio, dividend yield, and performance metrics

Day's Range$69.85 - $70.83
52-Week High$74.35
52-Week Low$45.80
Open$70.39
Volume93.14K
Average Volume (3M)140.37K
Assets (AUM)478.93M
Expense Ratio0.35%
Total Holdings66
Inception DateJun 19, 2006
1 Day Change-0.78%
1 Month Change-0.20%
6 Month Change27.59%
YTD Change27.48%
1 Year Change47.64%
52-Week Change47.86%
5 Year Change45.71%
10 Year Change59.52%
50-Day MA$69.61
200-Day MA$59.90
RSI48.62
Stochastic %K11.79
Stochastic %D21.11
Annual Dividend$0.59
Dividend Yield0.83%
Last Dividend Ex-DateSep 24, 2026
Dividend Growth YoY-2.34%

Frequently Asked Questions About State Street SPDR S&P Pharmaceuticals ETF

What is the current price of XPH?

The latest XPH price is $70.38. The 52-week range is $45.80–$74.34. XPH has returned 47.9% over the past 52 weeks.

What is the expense ratio for XPH?

XPH's annual expense ratio is 0.35%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.

Does XPH pay dividends?

Yes, XPH pays a 0.83% dividend yield. The last ex-dividend date was 2026-09-24. View full dividend history in the Dividends section.

What are the top holdings of XPH?

XPH's largest holdings are Corcept Therapeutics Incorporated (4.4%), Organon & Co. (3.7%), Crinetics Pharmaceuticals, Inc. (3.6%) (combined weight: 11.7%). The fund holds 66 total positions. View the complete portfolio breakdown in the Holdings section.

How does XPH compare to similar ETFs?

Compare XPH (0.35% expense ratio, $479M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.